Clinical Trial Update: Safety Study Looking at the Use of a Natural Killer Cell Line Against Hematological Malignancies [Phase 1]

View source ↗

Summary

Phase 1 safety study evaluating a natural killer (NK) cell line for hematologic cancers has completed, assessing its use against leukemia, lymphoma, multiple my…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma
• Leukemia
• Lymphoma
• Multiple Myeloma

Drugs mentioned

• NK-92 cell line (Natural killer cell line)

Snippet

Sponsor: University Health Network, Toronto | Conditions: Leukemia, Lymphoma | Phase 1 | Status: COMPLETED